CRISPR Therapeutics AG (LTS:0VRQ) Total Liabilities: $911.26 Mil (As of Mar. 2026)


LTS:0VRQ CRISPR Therapeutics AG LTS:0VRQ
46 GF Score
Price $59.25
GF Value $2.74
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Total Liabilities?

CRISPR Therapeutics AG LTS:0VRQ 46 Total Liabilities is $911.26 Mil as of Mar. 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 46/100 and a GF Value™ of $2.74 (Significantly Overvalued). The stock has 3 warning signs investors should review.

CRISPR Therapeutics AG's Total Liabilities for the quarter that ended in Mar. 2026 was $911.26 Mil.

CRISPR Therapeutics AG's quarterly Total Liabilities increased from Sep. 2025 ($329.33 Mil) to Dec. 2025 ($343.43 Mil) and increased from Dec. 2025 ($343.43 Mil) to Mar. 2026 ($911.26 Mil).

CRISPR Therapeutics AG's annual Total Liabilities declined from Dec. 2023 ($346.77 Mil) to Dec. 2024 ($309.95 Mil) but then increased from Dec. 2024 ($309.95 Mil) to Dec. 2025 ($343.43 Mil).

CRISPR Therapeutics AG Total Liabilities Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Total Liabilities Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 352.42 367.58 346.77 309.95 343.43

CRISPR Therapeutics AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 336.94 318.59 329.33 343.43 911.26
LTS:0VRQ
46GF Score
CRISPR Therapeutics AG LTS:0VRQ
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CRISPR Therapeutics AG's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=149.12+(188.168+6.142
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=343.43

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=2265.243-1921.813
=343.43

CRISPR Therapeutics AG's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=136.286+(769.03+5.9480000000001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=911.26

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2725.82-1814.556
=911.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $911.26 Mil mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a Total Liabilities of $911.26 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Total Liabilities too high?
CRISPR Therapeutics AG's current Total Liabilities is $911.26 Mil. Overall, CRISPR Therapeutics AG has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Total Liabilities compare to ORKA and TVTX?
CRISPR Therapeutics AG's Total Liabilities of $911.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Total Liabilities is $911.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.74, compared to a current price of $59.25 — trading 2062.4% above its estimated fair value. The current Total Liabilities is $911.26 Mil. CRISPR Therapeutics AG's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Total Liabilities is $911.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of $59.25 is trading 2062.4% above its estimated GF Value™ of $2.74. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for LTS:0VRQ:

  • Total Liabilities: $911.26 Mil
  • GF Value™: $2.74 vs. price of $59.25 (2062.4% above fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
46GF Score

Get the complete analysis for LTS:0VRQ

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.25
Price
$2.74
GF Value